Related Experiment Video
Updated: May 18, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
[Markers of endothelial activation in rheumatoid arthritis]
Aim:
To study relationships between endothelial activation parameters and inflammatory activity markers in patients with rheumatoid arthritis (RA).
Subjects And Methods:
Fifty-three RA patients aged 19 to 62 years were examined. A control group comprised 28 apparently healthy individuals. The markers of endothelial activation, the parameters of RA activity, and their relationship were studied.
Results:
There was an elevation in the level of interleukin-8 (IL-8) to 413 (295; 547) pg/ml as compared to the control group 208 (207; 212) pg/ml. In the RA group, the concentration of soluble vascular cell adhesion molecule 1 (sVCAM-1) increased up to 1929 (1297.6; 2739.6) ng/ml whereas in the control group it was 750 (734; 762) ng/ml (p < 0.001). In the patients with RA, the concentration of von Willebrand factor antigen (vWFAg) reached 1.4 (0.8; 1.9) IU/ml; in the control group, it was 0.6 (0.3; 0.8) IU/ml. In the RA group, the level of desquamated endotheliocytes (DE) was higher than that in the control group. Positive correlations were found between the markers of vascular endothelial activation and those of inflammation. There was a positive correlation between C-reactive protein (CRP), rheumatoid factor (RF), sVCAM-1, and DE. Significant positive correlations were observed between DAS28 and the inflammatory markers RF and CRP (R = 0.66; p < 0.05 and R = 0.4; p < 0.05) and the endothelial activation markers sVCAM-1 and vWFAg (R = 0.8; p < 0.05 and R = 0.3; p < 0.05, respectively).
Conclusion:
The patients with RA had elevated IL-8, sVCAM-1, and vWFAg levels. Enhanced RA activity resulted in endothelial damage.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Chronic Inflammation: Introduction
Acute Inflammation III: Local and Systemic Effects
Rheumatic Heart Disease I: Introduction
